Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -27.1 Million USD | 93.3% |
| 2022 | -404.5 Million USD | -117.59% |
| 2021 | -185.9 Million USD | -137.03% |
| 2020 | 502 Million USD | 155.54% |
| 2019 | -903.9 Million USD | -19.06% |
| 2018 | -759.2 Million USD | -594.73% |
| 2017 | -109.28 Million USD | -102.08% |
| 2016 | -54.07 Million USD | 87.53% |
| 2015 | -433.59 Million USD | -128.62% |
| 2014 | -189.65 Million USD | -530.17% |
| 2013 | -30.09 Million USD | -113.26% |
| 2012 | 227.05 Million USD | 572.27% |
| 2011 | -48.07 Million USD | -201.3% |
| 2010 | 47.45 Million USD | 122.92% |
| 2009 | -207.07 Million USD | 14.68% |
| 2008 | -242.7 Million USD | 18.18% |
| 2007 | -296.63 Million USD | -683.17% |
| 2006 | -37.87 Million USD | -344.49% |
| 2005 | 15.49 Million USD | -84.31% |
| 2004 | 98.76 Million USD | 3.39% |
| 2003 | 95.53 Million USD | -20.44% |
| 2002 | 120.07 Million USD | 356.47% |
| 2001 | -46.81 Million USD | -65.45% |
| 2000 | -28.29 Million USD | -44.37% |
| 1999 | -19.6 Million USD | -25.64% |
| 1998 | -15.6 Million USD | 33.05% |
| 1997 | -23.3 Million USD | 9.69% |
| 1996 | -25.8 Million USD | -11.21% |
| 1995 | -23.2 Million USD | -105.31% |
| 1994 | -11.3 Million USD | -126.0% |
| 1993 | -5 Million USD | 47.92% |
| 1992 | -9.6 Million USD | 58.97% |
| 1991 | -23.4 Million USD | -7.34% |
| 1990 | -21.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 101.3 Million USD | 473.8% |
| 2024 Q3 | 692.2 Million USD | -10.73% |
| 2024 Q2 | 775.4 Million USD | 665.45% |
| 2023 Q1 | -1.21 Billion USD | -200.25% |
| 2023 Q2 | 765 Million USD | 162.99% |
| 2023 FY | -27.1 Million USD | 93.3% |
| 2023 Q3 | 550.3 Million USD | -28.07% |
| 2023 Q4 | -27.1 Million USD | -104.92% |
| 2022 Q2 | -694.4 Million USD | -7.61% |
| 2022 Q4 | -404.5 Million USD | 48.81% |
| 2022 FY | -404.5 Million USD | -117.59% |
| 2022 Q1 | -645.3 Million USD | -247.12% |
| 2022 Q3 | -790.2 Million USD | -13.8% |
| 2021 Q3 | -733.8 Million USD | -217.33% |
| 2021 Q4 | -185.9 Million USD | 74.67% |
| 2021 Q1 | 1.25 Billion USD | 150.76% |
| 2021 FY | -185.9 Million USD | -137.03% |
| 2021 Q2 | 625.4 Million USD | -50.32% |
| 2020 FY | 502 Million USD | 155.54% |
| 2020 Q4 | 502 Million USD | -55.25% |
| 2020 Q1 | -1.49 Billion USD | -65.17% |
| 2020 Q2 | 223.7 Million USD | 114.98% |
| 2020 Q3 | 1.12 Billion USD | 401.48% |
| 2019 Q3 | -672.1 Million USD | -101.11% |
| 2019 Q4 | -903.9 Million USD | -34.49% |
| 2019 Q2 | -334.2 Million USD | 66.53% |
| 2019 Q1 | -998.6 Million USD | -31.53% |
| 2019 FY | -903.9 Million USD | -19.06% |
| 2018 Q3 | -380.64 Million USD | -79.57% |
| 2018 Q1 | -314.84 Million USD | -188.11% |
| 2018 FY | -759.2 Million USD | -594.73% |
| 2018 Q2 | -211.97 Million USD | 32.67% |
| 2018 Q4 | -759.2 Million USD | -99.45% |
| 2017 FY | -109.28 Million USD | -102.08% |
| 2017 Q3 | -89.74 Million USD | -108.04% |
| 2017 Q4 | -109.28 Million USD | -21.76% |
| 2017 Q1 | -104.16 Million USD | -92.63% |
| 2017 Q2 | -43.14 Million USD | 58.59% |
| 2016 Q4 | -54.07 Million USD | 89.95% |
| 2016 FY | -54.07 Million USD | 87.53% |
| 2016 Q2 | -284.98 Million USD | -17.77% |
| 2016 Q3 | -538.13 Million USD | -88.83% |
| 2016 Q1 | -241.98 Million USD | 44.19% |
| 2015 Q2 | -2.5 Million USD | 92.92% |
| 2015 Q1 | -35.43 Million USD | 81.32% |
| 2015 Q4 | -433.59 Million USD | -66.95% |
| 2015 Q3 | -259.72 Million USD | -10259.79% |
| 2015 FY | -433.59 Million USD | -128.62% |
| 2014 Q4 | -189.65 Million USD | -133.45% |
| 2014 FY | -189.65 Million USD | -530.17% |
| 2014 Q1 | 69.25 Million USD | 330.11% |
| 2014 Q2 | -82.28 Million USD | -218.82% |
| 2014 Q3 | -81.24 Million USD | 1.27% |
| 2013 Q3 | 218.96 Million USD | 138.97% |
| 2013 Q2 | 91.62 Million USD | -67.55% |
| 2013 Q1 | 282.38 Million USD | 24.37% |
| 2013 FY | -30.09 Million USD | -113.26% |
| 2013 Q4 | -30.09 Million USD | -113.74% |
| 2012 Q4 | 227.05 Million USD | -31.76% |
| 2012 Q2 | 274.28 Million USD | 493.08% |
| 2012 Q1 | 46.24 Million USD | 196.2% |
| 2012 FY | 227.05 Million USD | 572.27% |
| 2012 Q3 | 332.73 Million USD | 21.31% |
| 2011 Q1 | 24.77 Million USD | -47.8% |
| 2011 Q4 | -48.07 Million USD | -4.53% |
| 2011 FY | -48.07 Million USD | -201.3% |
| 2011 Q2 | -93.97 Million USD | -479.33% |
| 2011 Q3 | -45.99 Million USD | 51.06% |
| 2010 Q1 | 39.58 Million USD | 119.12% |
| 2010 Q2 | 45.8 Million USD | 15.71% |
| 2010 Q3 | -166.27 Million USD | -462.98% |
| 2010 Q4 | 47.45 Million USD | 128.54% |
| 2010 FY | 47.45 Million USD | 122.92% |
| 2009 Q4 | -207.07 Million USD | -10.29% |
| 2009 Q1 | -199.09 Million USD | 17.97% |
| 2009 Q3 | -187.75 Million USD | 9.97% |
| 2009 FY | -207.07 Million USD | 14.68% |
| 2009 Q2 | -208.54 Million USD | -4.74% |
| 2008 FY | -242.7 Million USD | 18.18% |
| 2008 Q2 | -173.47 Million USD | 45.94% |
| 2008 Q3 | -197.18 Million USD | -13.66% |
| 2008 Q4 | -242.7 Million USD | -23.09% |
| 2008 Q1 | -320.87 Million USD | -8.17% |
| 2007 Q2 | 90.35 Million USD | 107.64% |
| 2007 Q3 | 102.58 Million USD | 13.53% |
| 2007 Q4 | -296.63 Million USD | -389.16% |
| 2007 FY | -296.63 Million USD | -683.17% |
| 2007 Q1 | 43.51 Million USD | 214.89% |
| 2006 Q3 | 32.33 Million USD | -61.97% |
| 2006 Q1 | 17.66 Million USD | 14.05% |
| 2006 FY | -37.87 Million USD | -344.49% |
| 2006 Q2 | 85.04 Million USD | 381.32% |
| 2006 Q4 | -37.87 Million USD | -217.13% |
| 2005 Q4 | 15.49 Million USD | -35.2% |
| 2005 Q3 | 23.9 Million USD | -56.37% |
| 2005 Q2 | 54.79 Million USD | 5.01% |
| 2005 Q1 | 52.18 Million USD | -47.16% |
| 2005 FY | 15.49 Million USD | -84.31% |
| 2004 Q3 | 94.95 Million USD | 23.05% |
| 2004 Q2 | 77.16 Million USD | 197.18% |
| 2004 FY | 98.76 Million USD | 3.39% |
| 2004 Q4 | 98.76 Million USD | 4.02% |
| 2004 Q1 | 25.96 Million USD | -72.82% |
| 2003 Q2 | 75.48 Million USD | 790.71% |
| 2003 FY | 95.53 Million USD | -20.44% |
| 2003 Q4 | 95.53 Million USD | 206.95% |
| 2003 Q3 | -89.32 Million USD | -218.32% |
| 2003 Q1 | 8.47 Million USD | -92.94% |
| 2002 Q3 | 124.66 Million USD | -4.8% |
| 2002 Q4 | 120.07 Million USD | -3.68% |
| 2002 Q1 | 64.99 Million USD | 238.83% |
| 2002 Q2 | 130.95 Million USD | 101.47% |
| 2002 FY | 120.07 Million USD | 356.47% |
| 2001 Q4 | -46.81 Million USD | 52.13% |
| 2001 FY | -46.81 Million USD | -65.45% |
| 2001 Q1 | -181.16 Million USD | -540.24% |
| 2001 Q2 | -140.63 Million USD | 22.37% |
| 2001 Q3 | -97.8 Million USD | 30.46% |
| 2000 FY | -28.29 Million USD | -44.37% |
| 2000 Q1 | -8.42 Million USD | 57.03% |
| 2000 Q3 | -46.63 Million USD | 40.44% |
| 2000 Q2 | -78.3 Million USD | -829.81% |
| 2000 Q4 | -28.29 Million USD | 39.33% |
| 1999 Q1 | -17.9 Million USD | -14.74% |
| 1999 FY | -19.6 Million USD | -25.64% |
| 1999 Q3 | -20.2 Million USD | -19.53% |
| 1999 Q2 | -16.9 Million USD | 5.59% |
| 1999 Q4 | -19.6 Million USD | 2.97% |
| 1998 Q1 | -14.5 Million USD | 37.77% |
| 1998 Q2 | -17.7 Million USD | -22.07% |
| 1998 Q3 | -18.1 Million USD | -2.26% |
| 1998 Q4 | -15.6 Million USD | 13.81% |
| 1998 FY | -15.6 Million USD | 33.05% |
| 1997 Q1 | -20.1 Million USD | 22.09% |
| 1997 FY | -23.3 Million USD | 9.69% |
| 1997 Q3 | -33.5 Million USD | 24.04% |
| 1997 Q4 | -23.3 Million USD | 30.45% |
| 1997 Q2 | -44.1 Million USD | -119.4% |
| 1996 Q1 | -3.2 Million USD | 86.21% |
| 1996 Q4 | -25.8 Million USD | 9.47% |
| 1996 Q3 | -28.5 Million USD | 29.28% |
| 1996 FY | -25.8 Million USD | -11.21% |
| 1996 Q2 | -40.3 Million USD | -1159.38% |
| 1995 Q1 | -4 Million USD | 64.6% |
| 1995 Q3 | 4.4 Million USD | 175.86% |
| 1995 Q4 | -23.2 Million USD | -627.27% |
| 1995 Q2 | -5.8 Million USD | -45.0% |
| 1995 FY | -23.2 Million USD | -105.31% |
| 1994 Q2 | -8.6 Million USD | -320.51% |
| 1994 Q1 | 3.9 Million USD | 178.0% |
| 1994 FY | -11.3 Million USD | -126.0% |
| 1994 Q4 | -11.3 Million USD | -126.0% |
| 1994 Q3 | -5 Million USD | 41.86% |
| 1993 Q3 | -32 Million USD | -31900.0% |
| 1993 FY | -5 Million USD | 47.92% |
| 1993 Q2 | -100 Thousand USD | 95.83% |
| 1993 Q1 | -2.4 Million USD | 75.0% |
| 1993 Q4 | -5 Million USD | 84.38% |
| 1992 Q4 | -9.6 Million USD | 26.15% |
| 1992 Q3 | -13 Million USD | 20.25% |
| 1992 Q2 | -16.3 Million USD | 18.91% |
| 1992 Q1 | -20.1 Million USD | 14.1% |
| 1992 FY | -9.6 Million USD | 58.97% |
| 1991 Q3 | -34.2 Million USD | 11.86% |
| 1991 FY | -23.4 Million USD | -7.34% |
| 1991 Q2 | -38.8 Million USD | 0.0% |
| 1991 Q4 | -23.4 Million USD | 31.58% |
| 1990 Q4 | -21.8 Million USD | 0.0% |
| 1990 FY | -21.8 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 68.892% |
| Dynavax Technologies Corporation | 106.63 Million USD | 125.414% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 19.17% |
| Perrigo Company plc | 3.32 Billion USD | 100.816% |
| Illumina, Inc. | 1.21 Billion USD | 102.232% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.101% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 76.205% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.329% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.211% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 118.68% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 477.07% |
| Waters Corporation | 1.96 Billion USD | 101.382% |
| Biogen Inc. | 6.28 Billion USD | 100.431% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -281.69% |
| Evolus, Inc. | 63.7 Million USD | 142.538% |
| Adicet Bio, Inc. | -142 Million USD | 80.917% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -200.577% |
| bluebird bio, Inc. | 108.57 Million USD | 124.961% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 105.908% |
| FibroGen, Inc. | 56.76 Million USD | 147.739% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 102.367% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 488.917% |
| Homology Medicines, Inc. | 18.43 Million USD | 246.987% |
| Geron Corporation | 14.76 Million USD | 283.592% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 101.709% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 113.682% |
| Myriad Genetics, Inc. | 88.1 Million USD | 130.76% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 50.052% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 75.674% |
| Zoetis Inc. | 4.76 Billion USD | 100.569% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -169.089% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 101.292% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 107.155% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.717% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -85.973% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 102.57% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 184.993% |
| Verastem, Inc. | -37.27 Million USD | 27.303% |
| Nektar Therapeutics | 210.24 Million USD | 112.89% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 86.438% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 26.367% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 102.798% |
| OPKO Health, Inc. | 230.68 Million USD | 111.748% |
| Exelixis, Inc. | -73.05 Million USD | 62.902% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 115.285% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 79.985% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 82.056% |
| uniQure N.V. | -102.95 Million USD | 73.677% |
| Imunon, Inc. | -4.69 Million USD | -476.685% |
| Blueprint Medicines Corporation | 702.83 Million USD | 103.856% |
| Insmed Incorporated | 721.62 Million USD | 103.755% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.963% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 13.188% |
| TG Therapeutics, Inc. | 17.86 Million USD | 251.719% |
| Incyte Corporation | -3.17 Billion USD | 99.146% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 103.539% |